SCHEMBL7987996

SCHEMBL7987996

CNC(=O)C1CCc2c(cnn2S(=O)(=O)c2ccc(C)cc2)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
LMNA P02545 3/20 0.39
GAA P10253 3/20 0.39
USP2 O75604 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
EPHX2 P34913 1/20 0.39
NPSR1 Q6W5P4 2/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 3/20 0.38
RECQL P46063 2/20 0.38
MAPK1 P28482 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
POLB P06746 2/20 0.38
KMT2A Q03164 2/20 0.37
GLA P06280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7974591 0.89 EPHX2 (0.49) ALDH1A1LMNAGAAEPHX2TSHR
SCHEMBL1417779 0.89 ALDH1A1 (0.42) ALDH1A1GAASMN1; SMN2NPSR1TSHR
SCHEMBL7991790 0.76 GAA (0.40) ALDH1A1LMNAGAAUSP2SMN1; SMN2
SCHEMBL7987717 0.69 HTR6 (0.46) ALDH1A1RECQLPOLBKMT2AMAPT
SCHEMBL1417900 0.68 ESR2 (0.45) ALDH1A1LMNAGAAUSP2SMN1; SMN2
SCHEMBL15904926 0.68 ACHE (0.42) ALDH1A1NPC1RAB9ALMNAGAA
SCHEMBL12670982 0.67 ALDH1A1 (0.39) ALDH1A1LMNAGAAUSP2SMN1; SMN2
SCHEMBL7985821 0.66 EPHX2 (0.49) ALDH1A1LMNAGAAEPHX2HPGD
SCHEMBL12670985 0.66 KDM2B (0.38) ALDH1A1NPC1TSHRRECQLPOLB
SCHEMBL7969583 0.65 NPSR1 (0.36) ALDH1A1LMNAGAAUSP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
WO-2010001946-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF アステラス製薬株式会社 (JP) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF HSD11B1, HSD11B2, HSD3B1 ALDH1A1 359/4885NPC1 708/4885RAB9A 3358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.